Insider Selling: Billiontoone (NASDAQ:BLLN) CTO Sells $416,625.00 in Stock

Billiontoone, Inc. (NASDAQ:BLLN) CTO David Tsao sold 3,333 shares of the company’s stock in a transaction that occurred on Thursday, September 24th. The shares were sold at an average price of $125.00, for a total value of $416,625.00. Following the transaction, the chief technology officer directly owned 1,000 shares in the company, valued at approximately $125,000. This represents a 76.92% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

David Tsao also recently made the following trade(s):

• On Wednesday, September 9th, David Tsao sold 20,000 shares of Billiontoone stock. The shares were sold at an average price of $98.77, for a total value of $1,975,400.00.
• On Tuesday, August 25th, David Tsao sold 10,000 shares of Billiontoone stock. The shares were sold at an average price of $100.00, for a total transaction of $1,000,000.00.
• On Monday, August 10th, David Tsao sold 10,000 shares of Billiontoone stock. The stock was sold at an average price of $92.86, for a total transaction of $928,600.00.

Billiontoone Trading Down 9.9%

Shares of BLLN opened at $106.44 on Thursday. The firm has a market capitalization of $5.02 billion and a price-to-earnings ratio of 152.06. The company has a debt-to-equity ratio of 0.17, a current ratio of 11.69 and a quick ratio of 11.31. Billiontoone, Inc. has a 1-year low of $61.96 and a 1-year high of $150.44. The company has a 50-day moving average of $107.92 and a 200 day moving average of $99.53.

Billiontoone (NASDAQ:BLLN) last issued its earnings results on Wednesday, August 5th. The company reported $0.15 EPS for the quarter, hitting analysts’ consensus estimates of $0.15. Billiontoone had a net margin of 8.04% and a return on equity of 9.96%. The business had revenue of $109.45 million for the quarter. On average, research analysts expect that Billiontoone, Inc. will post 0.83 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on BLLN shares. JPMorgan Chase & Co. dropped their price target on Billiontoone from $145.00 to $130.00 and set an “overweight” rating on the stock in a research report on Thursday, August 6th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Billiontoone in a report on Friday, September 18th. Wall Street Zen downgraded shares of Billiontoone from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Guggenheim began coverage on shares of Billiontoone in a report on Monday, June 29th. They issued a “buy” rating and a $125.00 price target for the company. Finally, BTIG Research dropped their price objective on shares of Billiontoone from $142.00 to $130.00 and set a “buy” rating on the stock in a research note on Thursday, August 6th. Seven analysts have rated the stock with a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, Billiontoone currently has an average rating of “Hold” and an average target price of $125.88.

Institutional Trading of Billiontoone

A number of institutional investors have recently modified their holdings of BLLN. Integrated Wealth Concepts LLC purchased a new stake in Billiontoone during the second quarter valued at approximately $29,000. MCF Advisors LLC lifted its holdings in shares of Billiontoone by 330.8% during the 2nd quarter. MCF Advisors LLC now owns 448 shares of the company’s stock valued at $54,000 after purchasing an additional 344 shares during the last quarter. Thrive Wealth Management LLC purchased a new position in Billiontoone during the 2nd quarter worth $240,000. Caitong International Asset Management Co. Ltd acquired a new position in Billiontoone during the 4th quarter valued at about $230,000. Finally, Jasper Ridge Partners L.P. purchased a new stake in Billiontoone in the second quarter valued at about $615,000.

About Billiontoone

BillionToOne, Inc (NASDAQ:BLLN) is a molecular diagnostics company that develops blood-based genetic tests designed to provide more information from small amounts of cell-free DNA. The company’s platform uses proprietary molecular counting technology to improve the sensitivity and accuracy of diagnostic testing.

BillionToOne’s primary business is reproductive health testing. Its UNITY portfolio is designed to support prenatal screening, including testing for chromosomal conditions and single-gene disorders, and is intended to provide physicians and expectant parents with information from a maternal blood sample.